Biography
David Lyden, M.D., Ph.D. is the Stavros S. Niarchos Associate Professor in Pediatric Cardiology and Associate Professor of Pediatrics at Weill Cornell Medical College, where he is also an Associate Professor of Cell and Developmental Biology.
Dr. Lyden, who is a member of the Division of Pediatric Hematology and Oncology, received his PhD at the University of Vermont, where he also completed a Post-Doctoral Fellowship. Four years later, he completed his medical school degree at Brown University School of Medicine. After completing his residency in Pediatrics at Duke University Medical Center, Dr. Lyden went on to complete a fellowship in Pediatric Hematology-Oncology at the renowned Memorial Sloan-Kettering Cancer Center in New York City, where he later served as Chief Fellow.
He joined the Weill Cornell Medical College's Department of Pediatrics from the Cell Biology Department at Memorial Sloan-Kettering, where he was also a member of the Pediatric Brain Tumor Team. Dr. Lyden was one of the leaders of the research team at Sloan-Kettering that developed a strain of mouse that is immune to certain types of cancer, surviving injections of malignant cells that quickly raise lethal tumors in normal mice.
He was also a major contributor to the study that showed that bone marrow harbors the cells that are essential to building the lining of tumor blood vessels, a finding which may lead to more targeted treatment for cancer, including the use of antibodies to block the mobilization of bone marrow cells. Most recently, Dr. Lyden co-authored work demonstrating that bone-marrow-derived vascular stem cells contribute to angiogenesis and growth of certain tumors.
He is a member of the Professional Advisory Board of the Children's Brain Tumor Foundation (CBTF). In 2000, he received a Clinical Scientist Development Award from the Doris Duke Charitable Foundation.
